



Presbyterian Health Plan, Inc.
 Presbyterian Insurance Company, Inc.

NOTIFICATION OF FORMULARY CHANGES

The following summary describes changes to the Presbyterian Commercial Large Group Plans (Non-Metal Plans) Formularies effective 2024.

For the most recent list of drugs, information on obtaining a coverage determination or exception or other questions, please contact the Presbyterian Customer Service Center. You can reach them Monday through Friday from 8:00 a.m. to 5:00 p.m.

Phone: (505) 923-5678 or 1-800-356-2219
 (TTY 711)

Email: info@phs.org

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
09/05/2023	Abrysvo® 120mcg/0.5mL intramuscular solution	Formulary Addition	\$0, AL	\$0, AL		
01/01/2024	Accu-Chek® (Blood Glucose Monitors) Compact Plus, Guide, and Smartview	QL Decreased	T1, QL	T1, QL		
01/01/2024	Amjevita-Ped® (adalimumab-atto) 10 mg/0.2 mL, 20 mg/0.4 mL 15kg to <30kg prefilled syringes; 10 mg/0.2 mL and 20 mg/0.4 mL prefilled syringes; 40 mg/0.8 mL auto-injector	Formulary Addition	T4, PA, QL, SP	T4, PA, QL, SP		

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
09/05/2023	Arexvy® (<i>rsvpref3 vac recomb adjuvanted</i>) 120 mcg/0.5 mL intramuscular solution	Formulary Addition	\$0	\$0		
09/20/2023	brimonidine (generic for Alphagan® P) 0.1% ophthalmic solution	Formulary Addition	T2, ST	T2, ST		
09/20/2023	Alphagan® P (brimonidine) 0.1% ophthalmic solution	Formulary Deletion	NF	NF	brimonidine 0.1% ophthalmic solution (T3, ST)	brimonidine 0.1% ophthalmic solution (T3, ST)
01/01/2024	Eylea® HD (aflibercept) 8 mg/0.07 mL	Formulary Addition	MB	MB		
01/01/2024	fluticasone/salmeterol (generic for Advair®) 100/50 mcg and 200/50 mcg inhalation aerosol powder	AL Removed	T3, ST, QL	T3, ST, QL		
01/01/2024	Freestyle® (Continuous Glucose Monitors) Libre 2 and Libre 3	Criteria Update	T2, PA, QL	T2, PA, QL		
01/01/2024	lisdexamfetamine (generic for Vyvanse®) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg oral capsules	Formulary Addition	T3, PA, QL	T3, PA, QL		
01/01/2024	Vyvanse® (lisdexamfetamine) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg oral capsules	Formulary Deletion	NF	NF	lisdexamfetamine (generic for Vyvanse®) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg oral capsules (T2, PA, QL)	lisdexamfetamine (generic for Vyvanse®) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg oral capsules (T2, PA, QL)

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
01/08/2024	Flovent Diskus® (fluticasone) 50 mcg/act, 100 mcg/act, and 250 mcg/act; Flovent HFA® (fluticasone) 44 mcg/act, 110 mcg/act, 220 mcg/act	Manufacturer withdrawal	NF	NF	fluticasone diskus (generic for Flovent Diskus®) 50 mcg/act, 100 mcg/act (T2), and 250 mcg/act; fluticasone HFA (generic for Flovent HFA®) 44 mcg/act, 110 mcg/act, 220 mcg/act (T2)	fluticasone diskus (generic for Flovent Diskus®) 50 mcg/act, 100 mcg/act (T2), and 250 mcg/act; fluticasone HFA (generic for Flovent HFA®) 44 mcg/act, 110 mcg/act, 220 mcg/act (T2)
01/08/2024	fluticasone (generic for Flovent Diskus®); 50 mcg/act, 100 mcg/act, and 250 mcg/act; fluticasone (generic for Flovent HFA®) 44 mcg/act, 110 mcg/act, 220 mcg/act	Formulary Addition	T2	T2		
01/16/2024	Votrient® (pazopanib) 200 mg tablets	Formulary Deletion	NF	NF	pazopanib 200mg tablets (T4, PA, QL, SP)	pazopanib 200mg tablets (T4, PA, QL, SP)
01/16/2024	pazopanib (generic for Votrient®) 200 mg tablets	Formulary Addition	T4, PA, QL, SP	T4, PA, QL, SP		
01/22/2024	Freestyle Reader 3	Formulary Addition	T2, PA, QL	T2, PA, QL		
01/22/2024	amphetamine-dextroamphetamine (generic for Zenedi®) 5 mg, 10 mg tablet	AL Decreased	T1, QL, AL	T1, QL, AL		
01/22/2024	amphetamine-dextroamphetamine (generic for Adderall®)	AL Decreased	T1, QL, AL	T1, QL, AL		



Presbyterian Health Plan, Inc.
Presbyterian Insurance Company, Inc.

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
	5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg tablet					
02/05/2024	NP Thyroid 120 mg tablet	Formulary Addition	T1	T1		
02/09/2024	brimonidine (generic for Alphagan® P) 0.1 % ophthalmic solution	ST Removed	T2	T2		
02/09/2024	clarithromycin (generic for Biaxin®) 250 mg, 500 mg tablet; 125 mg/5mL, 250 mg/5mL suspension	QL Removed	T1	T1		
02/20/2024	Xarelto® (rivaroxaban) 2.5 mg tablet	PA Removed	T2, QL	T2, QL		
02/21/2024	Penbraya® (mening acyw(tet conj)-b(rcmb)) Intramuscular suspension	Formulary Addition	\$0	\$0		
02/21/2024	Bosulif® (bosutinib) 100 mg capsule	Formulary Addition	T4, PA, QL, SP	T4, PA, QL, SP		
03/01/2024	abiraterone (generic for Zytiga®) 250 mg tablet	PA Removed & Tier Lowered	T3, QL	T3, QL		
03/01/2024	Cabenuva® (cabotegravir and rilpivirine extended-release) 400 & 600 mg/2mL, 600 & 900 mg/3mL suspension	Formulary Addition	MB, PA	MB, PA		
03/01/2024	Dexcom® G7 (continuous glucose monitor)	Formulary Addition	T2, PA, QL	T2, PA, QL		
03/01/2024	Enbrel® (etanercept)	PA Updated	T4, PA, QL, SP	T4, PA, QL, SP		

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
	25mg/0.5mL solution and prefilled syringe; 50mg/mL auto-injector (Sureclick), cartridge (mini) and prefilled syringe					
03/01/2024	Orencia® (abatacept) 50mg/0.4mL, 87.5mg/0.7mL, 125mg/mL prefilled syringe	PA Updated	T4, PA, QL, SP	T4, PA, QL, SP		
03/01/2024	Valtoco® (diazepam) 5 mg, 7.5 mg, 10 mg nasal spray	Formulary Addition	T4, PA, QL	T4, PA, QL		
03/01/2024	Veltassa® (patiomer) 8.4 g, 16.8 g, 25.2g Single-use packets	AL Updated	T4, PA, QL	T4, PA, QL		
04/01/2024	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg injection	Formulary Addition	T2, PA, QL	T2, PA, QL		
04/01/2024	Ozempic® (semaglutide) (0.25 or 0.5mg/dose) 2mg/1.5mL, (0.25 or 0.5mg/dose) 2mg/3mL pen injector; (1mg/dose) 2mg/1.5mL, (1mg/dose) 4mg/3mL, (2mg/dose) 8mg/3mL pen injector	Formulary Deletion	NF	NF	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg injection (T2, PA, QL)	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg injection (T2, PA, QL)
04/01/2024	Rybelsus® (semaglutide) 3mg, 7mg, 14mg tablet	Formulary Deletion	NF	NF	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg,	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg,

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
					15mg injection (T2, PA, QL)	15mg injection (T2, PA, QL)
04/01/2024	Victoza® (liraglutide) 18mg/3mL pen injector	Formulary Deletion	NF	NF	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg injection (T2, PA, QL)	Mounjaro® (terzepatide) 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg injection (T2, PA, QL)
06/01/2024	Dupixent® (dupilumab) 100mg/0.67mL, 200mg/1.14mL, 300mg/2mL syringes	Criteria Update	T4, PA, QL, SP, NDS	T4, PA, QL, SP, NDS		
06/01/2024	Xolair® (omalizumab) 75mg/0.5ml, 150mg/mL, 300mg/mL prefilled syringes/auto-injectors; 150mg lyophilized powder in a single- dose vial for reconstitution	Criteria Update	MB, PA, NDS	MB, PA, NDS		
06/01/2024	teriparatide (generic for Forteo®) 600mcg/2.4ml Prefilled Pen	Formulary Addition	T4, PA, SP, NDS	T4, PA, SP, NDS		
06/01/2024	Forteo® (teriparatide) 600mcg/2.4ml Prefilled Pen	Formulary Deletion			teriparatide 600mcg/2.4ml Prefilled Pen (T4, PA, SP, NDS)	teriparatide 600mcg/2.4ml Prefilled Pen (T4, PA, SP, NDS)
06/01/2024	risperidone microspheres er (generic for Risperdal Consta®) 12.5mg, 25mg, 37.5mg, 50mg Intramuscular Injection	Formulary Addition	T4, QL, AL, SP, NDS	T4, QL, AL, SP, NDS		
06/01/2024	Risperdal Consta® (risperidone microspheres er)	Formulary Deletion			risperidone microspheres er 12.5mg, 25mg, 37.5mg, 50mg	risperidone microspheres er 12.5mg, 25mg, 37.5mg, 50mg

Effective Date of Change	Drug Name	Description of Change	Commercial 4-Tier Formulary Coverage	Federal Employees Formulary Coverage	Commercial 4-Tier Formulary Alternative(s) and Tier (if applicable for formulary removals)	Federal Employees Formulary Alternative(s) and Tier (if applicable for formulary removals)
	12.5mg, 25mg, 37.5mg, 50mg Intramuscular Injection				Intramuscular Injection (T4, QL, AL, SP, NDS)	Intramuscular Injection (T4, QL, AL, SP, NDS)
06/01/2024	Durolane® (sodium hyaluronate) 60mg/3ml intra-articular injection	Formulary Addition	MB, PA			
06/01/2024	Brixadi® (buprenorphine) 8mg, 16mg, 24mg, 32mg, 64mg, 96mg, 128mg prefilled syringe	Formulary Addition	T4, QL	T4, QL		
06/01/2024	buprenorphine (generic for Subutex®) 8mg sublingual tablet	QL Update	T1, QL, AL, BH	T1, QL, AL, BH		
06/01/2024	buprenorphine-naloxone (generic for Suboxone®) 8-2mg sublingual tablet;	QL Update	T3, QL, AL, BH	T3, QL, AL, BH		

MB= Medical Benefit, **PA** = Prior Authorization required, **QL** = Quantity Limit, **SP** = Specialty Pharmacy required, **ST** = Step Therapy, **AL**=Age Limit

For more information on Presbyterian’s Nondiscrimination Notice, go to <https://www.phs.org/nondiscrimination>.